Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Codexis and Axolabs Partner to Advance Enzymatic RNA Manufacturing | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Codexis and Axolabs Partner to Advance Enzymatic RNA Manufacturing

Axolabs to evaluate Codexis’ ECO Synthesis Manufacturing Platform.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Codexis Inc., a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and Axolabs, an oligonucleotide Contract Research Development and Manufacturing organization (CRDMO), have entered into an agreement under which Axolabs will evaluate Codexis’ ECO Synthesis Manufacturing Platform.

This partnership provides Axolabs access to an innovative, scalable RNA manufacturing solution powered by enzymatic synthesis. The agreement also paves the way for future licensing discussions and potentially broader adoption of the platform.

“Part of our mission is to expand the reach of our ECO Synthesis Manufacturing Platform through collaborations with best-in-class CDMOs,” said Alison Moore, President & CEO of Codexis. “Axolabs is an industry-leading CRDMO, and we are delighted to enter into this partnership with them to enable more efficient manufacturing of oligonucleotide therapeutics that address large markets.”

Kathleen Campau, Senior Director of Operations for Axolabs said, “This technology has the potential to be pivotal to how therapeutic oligonucleotides are manufactured at scale in the future, enabling more sustainable and cost-effective production. At Axolabs, we are committed to advancing the science behind therapeutic oligonucleotides, and this partnership builds on our long-standing legacy of technology leadership in the field.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics